Navigation Links
PharmAthene's Recombinant Butyrylcholinesterase (rBChE) May Play A Neuroprotective Role in Alzheimer's Disease
Date:4/9/2008

effective both when inhaled and when absorbed through the skin. Nerve agents can be classified as either G-agents (sarin, soman, tabun) or V-agents (VX), both of which are exceedingly toxic.

About PharmAthene, Inc.

PharmAthene (Amex: PIP) was formed to meet the critical needs of the United States and its allies by developing and commercializing medical countermeasures against biological and chemical weapons. PharmAthene's lead programs include Valortim(TM) for the prevention and treatment of anthrax infection and Protexia(R) for the prevention and treatment of morbidity and mortality associated with exposure to chemical nerve agents. For more information about PharmAthene, please visit http://www.PharmAthene.com.

About Yissum:

Yissum was founded in 1964 to protect the Hebrew University's intellectual property and commercialise it. An estimated $1 billion in annual sales are generated by products based on Hebrew University technologies licensed out by Yissum. Ranked among the top technology transfer companies in the world, Yissum has registered 5500 patents covering 1600 inventions; licensed out 480 technologies and spun out 65 companies. Yissum's business partners span the globe and include companies such as Novartis, Microsoft, Johnson & Johnson, Merck, Intel, Teva and many more.

Statement on Cautionary Factors

Except for the historical information presented herein, matters discussed may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievem
'/>"/>

SOURCE PharmAthene, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. AlphaMed Pharmaceuticals Announces Breakthrough in the Development of Recombinant Alpha 1-Antitrypsin
2. Baxter Announces Recombinant Factor IX Development Program For Hemophilia B
3. CSL Behring Study in Animal Models Shows Feasibility of Developing a Half-Life Extended Recombinant FVIIa that Retains Biologic Activity
4. Inspiration Biopharmaceuticals Announces Filing of IND for Novel Recombinant Factor IX Product, IB1001, for the Treatment of Hemophilia B
5. CEL-SCI Presents Data for CEL-1000 as a Vaccine Adjuvant with Recombinant Hepatitis B Virus Protein
6. Targeted Genetics Reports on Recombinant DNA Advisory Committee (RAC) Review of its Phase 1/2 Trial of tgAAC94 for Rheumatoid Arthritis
7. Tart Cherries May Reduce Inflammation, Lower Risk for Type 2 Diabetes & Heart Disease
8. Shire Strives to Increase Adherence Among Chronic Kidney Disease Stage 5 Patients
9. Dutch Top Institute Allocates 150 Million Euro to R&D Projects Targeting Early Diagnosis and Treatment of Disease
10. Lilly Launches Its First Phase III Trial for Treatment of Alzheimers Disease
11. Early Research Suggests Umbilical Cord Blood Cell Therapy May Reduce Progression of Alzheimers Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... Oct. 22, 2014   Surefire Medical , Inc., ... designed to maximize targeted delivery of embolization agents in ... that oncologist John R. Daniels , MD of ... and surgical oncologist Steven C. Katz , MD ... Company,s Scientific Advisory Board (SAB).    "The ...
(Date:10/22/2014)... and AUSTIN, Texas , Oct. ... LLC today announced they have entered into a ... immunotherapies designed to target cancers. PhosImmune ... displayed on the surfaces of tumor cells in ... (PTTs), derived from proteins that play a role ...
(Date:10/22/2014)... Calif. , Oct. 22, 2014 /PRNewswire/ ... ), a biopharmaceutical company leading the discovery ... today announced that it has demonstrated human ... ongoing clinical study evaluating RG-101, a wholly-owned, ... treatment of hepatitis C virus infection ("HCV").  ...
Breaking Medicine Technology:Surefire Medical's Scientific Advisory Board Expands, Broadens Clinical Trial Expertise 2Biotech Companies To Co-Discover And Co-Develop Antibodies Targeting Novel Phosphopeptide Tumor Targets 2A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 2A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 3A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 4A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 5A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 6A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 7A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 8
... Medical Hematology and Oncology CHU Lapeyronie, Montpellier ... that has long been recognized as a marker ... range of diagnostic markers to monitor infection and ... a necessity throughout the health care sector, it ...
... ,Since the first system was invented in 1957, ... patient care. During the 1960s, blood gas analysis ... considered "the most important laboratory test for critically ... Dr. John Severinghaus, inventor of the blood gas ...
Cached Medicine Technology:Near-Patient Testing: The Advantages of C-Reactive Protein in Hematological Testing 2Near-Patient Testing: The Advantages of C-Reactive Protein in Hematological Testing 3Near-Patient Testing: The Advantages of C-Reactive Protein in Hematological Testing 4Blood Gas Analysis: The Pros and Cons of Point-Of-Care Testing 2Blood Gas Analysis: The Pros and Cons of Point-Of-Care Testing 3Blood Gas Analysis: The Pros and Cons of Point-Of-Care Testing 4
(Date:10/22/2014)... October 22, 2014 Hay House is pleased ... Addiction and Upgrade Your Life (Paperback; $10.82) written by the ... & Recovery. This book is meant to help readers ... life of recovery. , Recovery 2.0 is not the ... Recovery 2.0 is a guide for what comes next. ...
(Date:10/22/2014)... Pass, OR (PRWEB) October 22, 2014 ... Southern California’s fresh water supply runs dangerously low, Southern ... change. Southern Oregon’s rivers, despite the lowest mountain snow ... even in late summer and early autumn.* That was ... authors of the new book “Hiking Southern Oregon,” during ...
(Date:10/22/2014)... Healthcare professionals who are looking for ... home or on-the-go via laptops, tablets or mobile ... premium Seminar-on-Demand CE courses. The new courses add ... hours of CE course offerings, allowing therapy ... such a diverse library, there’s something for everyone. ...
(Date:10/22/2014)... are only 24 hours in a day, that doesn’t seem to ... within their busy schedules for exercise and fitness. Fortunately, one does ... in shape. Here are five ways you can reach your fitness ... Your Commute , Consider riding a bike or taking the bus ... routine. If you must use your car to get to work, ...
(Date:10/22/2014)... King of Prussia, PA (PRWEB) October 22, 2014 ... Group, is recognized as an industry leader with over ... industry award winning team leader in the areas related ... In addition, Mr. Carlson is an Editorial Advisory Board ... Group Healthcare Council Educator. Blue Fin Group is ...
Breaking Medicine News(10 mins):Health News:Hay House Announces The Official Release of Recovery 2.0: Move Beyond Addiction and Upgrade Your Life 2Health News:Hay House Announces The Official Release of Recovery 2.0: Move Beyond Addiction and Upgrade Your Life 3Health News:Southern Oregon Is West’s Most Drought Proof Fresh Water Region Say Hiking Guide Authors 2Health News:Southern Oregon Is West’s Most Drought Proof Fresh Water Region Say Hiking Guide Authors 3Health News:Southern Oregon Is West’s Most Drought Proof Fresh Water Region Say Hiking Guide Authors 4Health News:Top Provider of Continuing Education at Home Releases 20 New Online Courses 2Health News:HealthGuideMD Presents Ways to Improve Your Exercise and Fitness 2Health News:Rich Carlson and Marc Duey to Hold Workshop at CBI’s Specialty Pharmacy and Distribution Networks Conference 2
... health, , THURSDAY, Feb. 18 (HealthDay News) -- New research ... a lot and those who have them less often: The ... more depressed. , The finding comes from a study ... episodic, if they occurred no more than 14 days a ...
... ... than later, says substance abuse expert Glenn Williams in his new Authentic/Biblica book, Talking Smack ... (PRWEB) February 18, 2010 ... COO Glenn Williams, a psychologist and substance abuse expert who has worked with parents and ...
... ... Carnie Wilson, will host a blog on The Fresh Diet, chronicling her quest to whittle ... Corner at blog.thefreshdiet.com where the daughter of the legendary Beach Boy, Brian Wilson, will discuss ... , ...
... ... related Q&A and social networking site, grows and adds new offerings, including answer customization ... ... SciAnswers.com , launched just over three months ago in November 2009 as a science ...
... ... freight import records from the public. Meanwhile, Microsoft, Google and Sony continue to import ... ... 17, 2010 -- Trade Privacy LLC , a trade data protection company, just ...
... , , , ... Ensign Group, Inc. (Nasdaq: ENSG ), the parent company of ... and assisted living companies, today reported record results for the fourth ... , Financial Highlights Include: , Total ...
Cached Medicine News:Health News:Talking Smack to Keep Kids Drug-Free 2Health News:Talking Smack to Keep Kids Drug-Free 3Health News:Carnie Wilson Blogs On The Fresh Diet 2Health News:SciAnswers.com Grows and Adds a Technical and Healthcare Professionals Job Board. 2Health News:SciAnswers.com Grows and Adds a Technical and Healthcare Professionals Job Board. 3Health News:Trade Privacy LLC: Research Concludes Apple Inc. Has Blocked Their Import Records from Public Access 2Health News:The Ensign Group Reports Fourth Quarter 2009 Adjusted Earnings of $0.43 Per Share; Issues 2010 Guidance 2Health News:The Ensign Group Reports Fourth Quarter 2009 Adjusted Earnings of $0.43 Per Share; Issues 2010 Guidance 3Health News:The Ensign Group Reports Fourth Quarter 2009 Adjusted Earnings of $0.43 Per Share; Issues 2010 Guidance 4Health News:The Ensign Group Reports Fourth Quarter 2009 Adjusted Earnings of $0.43 Per Share; Issues 2010 Guidance 5Health News:The Ensign Group Reports Fourth Quarter 2009 Adjusted Earnings of $0.43 Per Share; Issues 2010 Guidance 6Health News:The Ensign Group Reports Fourth Quarter 2009 Adjusted Earnings of $0.43 Per Share; Issues 2010 Guidance 7Health News:The Ensign Group Reports Fourth Quarter 2009 Adjusted Earnings of $0.43 Per Share; Issues 2010 Guidance 8Health News:The Ensign Group Reports Fourth Quarter 2009 Adjusted Earnings of $0.43 Per Share; Issues 2010 Guidance 9Health News:The Ensign Group Reports Fourth Quarter 2009 Adjusted Earnings of $0.43 Per Share; Issues 2010 Guidance 10Health News:The Ensign Group Reports Fourth Quarter 2009 Adjusted Earnings of $0.43 Per Share; Issues 2010 Guidance 11Health News:The Ensign Group Reports Fourth Quarter 2009 Adjusted Earnings of $0.43 Per Share; Issues 2010 Guidance 12Health News:The Ensign Group Reports Fourth Quarter 2009 Adjusted Earnings of $0.43 Per Share; Issues 2010 Guidance 13Health News:The Ensign Group Reports Fourth Quarter 2009 Adjusted Earnings of $0.43 Per Share; Issues 2010 Guidance 14Health News:The Ensign Group Reports Fourth Quarter 2009 Adjusted Earnings of $0.43 Per Share; Issues 2010 Guidance 15Health News:The Ensign Group Reports Fourth Quarter 2009 Adjusted Earnings of $0.43 Per Share; Issues 2010 Guidance 16
... 2000 assays are designed ... IMMULITE 2000, a high-throughput, ... analyzer. IMMULITE 2000 offers ... and a rapidly expanding ...
... IMMULITE 1000 assays are designed ... and IMMULITE 1000, continuous random ... simplicity in both design and ... found in a wide variety ...
... For The Detection ... Uses Of C-Peptide Measurement:, ... fasting hypoglycemia , Assisting ... diabetes mellitus , Differentiating ...
... Detection Of Serum C-Peptide ... Measurement:, Evaluating patients ... Assisting in the classification ... Differentiating insulin dependent patients ...
Medicine Products: